At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.

Sangamo Therapeutics hasn’t convinced a pharma company to buy its experimental gene therapy for Fabry disease after two years ...

The White House is clamping down on pharma’s ability to buy new molecules from Chinese biotechs; Sanofi, Merck and others ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

A genome-editing technique known as prime editing holds potential for treating many diseases by transforming faulty genes into functional ones. However, the process carries a small chance of inserting ...

In particular, Aradhye noted "increasing progress" at all levels of the innovation supply chain in China — "whether it's ...

This week marks the 30th anniversary of Jeans for Genes, one of the UK’s most recognised fundraising campaigns, which has ...

Also, there’s still no easy way to test AI designs of larger genomes. While some viruses can ‘boot up’ just from a DNA strand ...

Since she was a newborn, Ruby Benevedes has shown great strength despite living with an advanced form of sickle cell disease.

Researchers at Tel Aviv University have developed a new approach for using locked nucleic acids (LNAs)—a particularly stable ...

Researchers in Berlin have used base editing to repair mutations that cause the kidney disorder ADPKD in cells from both mice ...

The era of digital twins offers a future where deep biology, AI and real-world data combine to make medicine more personal, ...